Technique for the administration of high-dose-rate brachytherapy to the bile duct using a nasobiliary catheter

Publication date: July–August 2018
Source:Brachytherapy, Volume 17, Issue 4
Author(s): Christopher L. Deufel, Keith M. Furutani, Robert A. Dahl, Michael P. Grams, Luke B. McLemore, Christopher L. Hallemeier, Michelle Neben-Wittich, James A. Martenson, Michael G. Haddock
PurposeCholangiocarcinoma patients who are potential candidates for liver transplantation may be treated with high-dose-rate (HDR) brachytherapy using a minimally invasive nasobiliary catheter in an effort to escalate the radiotherapy dose to the tumor and maximize local control rates. This work describes the equipment, procedures, and quality assurance (QA) that enables successful administration.Methods and MaterialsThis work describes the nasobiliary catheter placement, simulation, treatment planning, treatment delivery, and QA. In addition, a chart review was performed of all patients who received endoscopic retrograde cholangiopancreatography for HDR bile duct brachytherapy at our institution from 2007 to 2017. The review evaluated how many patients were treated and the number of patients who could not be treated because of anatomic and/or equipment limitations.ResultsFrom 2007 to 2017, 122 cholangiocarcinoma patients have been treated with HDR brachytherapy using a nasobiliary catheter. Three patients underwent catheter placement but did not receive brachytherapy treatment due to catheter migration between placement and treatment or because the HDR afterloader was unable to extend the source wire into the treatment site. Periodic QA is recommended for ensuring whether the HDR afterloader is capable of extending the source wire through an extensive and curved path.ConclusionsIntraluminal HDR brachytherapy with a nasobiliary catheter can be successfully administered. Procedures and QA are described for ensuring safety and overcoming technical challenges.



https://ift.tt/2ln516Y